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The burden of influenza in sub-Saharan Africa (and 
specifically in South Africa (SA)) is substantial, with 
some studies suggesting elevated influenza-associated 
mortality rates compared with other regions.[1-3] It is 
estimated that between 6 734 and 11 619 individuals die 
of seasonal influenza-associated illness in SA each year.[4,5] Approximately 
5% of these deaths are in children aged <5 years. Among individuals aged 
≥5 years, an estimated 50% of influenza-associated deaths are in the 
elderly and ~30% are in HIV-infected individuals.[4]
The highest rates of influenza-associated hospitalisation are in the 
elderly aged ≥65 years, HIV-infected individuals and children aged 
<5 years.[4-9] Influenza infection may trigger exacerbations of diabetes 
and pulmonary (e.g. asthma) and cardiovascular disease. For this reason, 
people with underlying chronic medical conditions are at high risk of 
serious influenza complications, often resulting in hospitalisation and 
even death. Surveillance data from SA showed that having underlying 
illnesses (other than HIV) was a risk for influenza-associated mortality 
(odds ratio 2.9, 95% confidence interval (CI) 1.2 - 7.3).[7] Pregnant 
women also represent an important risk group for influenza-associated 
mortality.[8] Among an estimated 646 - 1 428 seasonal influenza-
associated deaths in women of childbearing age in SA in recent years, 
the majority (~90%) occurred in HIV-infected individuals and the 
influenza-associated mortality was three-fold higher (relative risk 2.8, 
95% CI 7 - 3.9) in pregnant compared with non-pregnant women.[8] 
Studies suggest that individuals with underlying tuberculosis may also 
be at increased risk of influenza-associated death.[10,11]
Influenza circulation in SA is highly seasonal, and the influenza 
season falls in the winter months. The average onset of the influenza 
season is the first week of June.[12] However, the season has started 
as early as the last week of April and as late as the first week of July. 
The average duration of the influenza season is 12 (range 7 - 25) 
weeks. During the influenza season in SA government facilities, 
approximately 14% of patients hospitalised with lower respiratory 
tract infection and 25% of patients with influenza-like illness will test 
positive for influenza on polymerase chain reaction analysis.
Vaccinating individuals at risk of severe influenza may provide 
direct protection for these individuals. In addition, vaccinating 
individuals in close contact with people at risk for severe influenza 
may provide indirect protection through preventing transmission 
to high-risk individuals. This strategy is especially important for 
individuals in whom influenza vaccine is not indicated, such as 
children aged <6 months (who may be protected through maternal 
immunisation). [13] It may also be useful for individuals in whom the 
immune response may be poor, e.g. children aged <2 years and the 
elderly. The trivalent inactivated influenza vaccine (IIV) has reduced 
effectiveness in certain groups, e.g. the elderly and children aged 
<2 years; however, even for these individuals IIV still provides some 
protection. Other products, e.g. high-dose influenza vaccine and 
adjuvanted vaccines, have been shown to be more effective in certain 
groups,[14] but these vaccines are not available in SA. The trivalent 
IIV has been shown to provide protection in pregnant women 
and their infants[13,15,16] and in HIV-infected adults without severe 
immunosuppression.[17] Data are unclear as to the effectiveness in 
HIV-infected children aged <5 years.[18]
Recommended influenza vaccine 
formulation for 2016
Influenza vaccine is updated frequently because circulating influenza 
viruses continuously evolve. The following strains have been 
recommended by the World Health Organization (WHO) for the 
trivalent IIV 2016 southern hemisphere influenza season:
• an A/California/7/2009 (H1N1)pdm09-like virus
• an A/Hong Kong/4801/2014 (H3N2)-like virus
• a B Brisbane/60/2008-like virus.
These recommendations include a change in the A (H3N2) and B 
strains when compared with the composition of the trivalent IIV used 
for the southern hemisphere during the 2015 season.
Standard-dose IIV should contain 15 μg of each haemagglutinin 
antigen in each 0.5 mL dose.
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Groups recommended 
for influenza vaccination
• Pregnant women irrespective of stage of 
pregnancy, or postpartum
• Individuals (adults or children) who 
are at high risk for influenza and its 
complications because of underlying 
medical conditions and who are 
receiving regular medical care for 
conditions such as chronic pulmonary 
(including tuberculosis) and cardiac 
diseases, chronic renal diseases, diabetes 
mellitus and similar metabolic disorders, 
individuals who are immunosuppressed 
and individuals who are morbidly obese 
(body mass index ≥40 kg/m2)
• HIV-infected individuals
• Healthcare workers
• Residents of old-age homes and chronic 
care and rehabilitation institutions
• Persons aged >65 years
• Children aged 6 months - 59 months
• Persons aged 6 months - ≤18 years on 
long-term aspirin therapy
• Adults and children who are family 
contacts of individuals at high risk of 
severe influenza
• Any persons wishing to minimise the 
risk of influenza acquisition, especially 
in workplace settings where large-scale 
absenteeism could cause significant 
economic losses.
Dosage
Recommended dosages for individuals of 
different age groups are set out in Table 1.
Contraindications
Persons with a history of severe (ana phylac-
tic) hypersensitivity to any components of 
the vaccine, including egg protein, or after a 
previous dose of any influenza vaccine.
Precautions
• Persons with moderate illness with or with-
out fever should preferably be immunised 
after symptoms have disappeared. Having a 
mild upper respiratory illness is not a reason 
to defer vaccination.
• A history of Guillain-Barré syndrome 
within 6 weeks of receipt of influenza 
vaccine.
Timing
Vaccines should be given sufficiently early 
to provide protection for the winter. A 
protective antibody response takes about 
2 weeks to develop.
Antiviral chemotherapy
Antiviral therapy is recommended as early 
as possible, ideally within 48 hours, for any 
patient with confirmed or suspected in fluen-
za who has complicated or severe illness or 
is at high risk of influenza complications. 
At present influenza A(H1N1)pdm09, 
A(H3N2) and B viruses remain sensitive to 
oseltamivir and zanamivir. High levels of 
resistance to adamantanes among influenza 
A viruses has been detected in a number 
of countries. The use of amantadine and 
rimantadine in the treatment of influenza is 
therefore not recommended. The dosages for 
treatment with oseltamivir and zanamivir 
are set out in Table 2.
Antiviral 
chemoprophylaxis
Antiviral chemoprophylaxis for contacts 
of persons with influenza is currently 
not recommended. An annual influenza 
vaccination is the best way to prevent 
influenza because it can be given before 
the possible exposures to influenza occur, 
and it can provide safe and effective 
immunity throughout the influenza season. 
However, WHO recommendations also 
advise presumptive treatment for high-
risk individuals (patients with severe 
immunosuppression or transplant patients) 
if any early signs of possible influenza 
infection are detected during the influenza 
season. Such individuals should be treated 
presumptively using the treatment regimen 
described above for a duration of 7 days, 
instead of the previously recommended 
long-term lower-dose chemoprophylaxis 
regimen.
For a more detailed description of antiviral 
management and chemoprophylaxis of 
influenza, please refer to the Healthcare 
Workers Handbook on influenza on the NICD 
website (http://www.nicd.ac.za/assets/files/
Healthcare%20Workers%20Handbook%20
on%20influenza%20in%20SA_%205%20
May%202015.pdf).
For the full report on recommended com-
position of influenza vaccines, refer to the 
WHO website (http://www.who.int/influenza/
vaccines/virus/recommendations/201509_
recommendation.pdf?ua=1).
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